Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romilkimab in diffuse cutaneous systemic sclerosis
NCT02921971Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2016
- Primary completion
- Jan 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing Romilkimab with Placebo (2 arms). Primary endpoint: Modified Rodnan Skin Score at 24 weeks. Started Dec 2016; status: completed.
02
Drugs
romilkimab
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT02921971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921971.